U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker ...